Smith & Nephew plc: Q2 and H1 2026 Financial Summary
Business Context and Reporting Period
This Form 6-K filing reports the Second Quarter and First Half 2026 results for Smith & Nephew plc, a global medical technology company. The reporting period covers the six months ended June 27, 2026. The company operates three primary business units: Sports Medicine & ENT, Advanced Wound Management, and Orthopaedics. The results reflect the ongoing execution of the "RISE" strategy, focusing on growth acceleration and return improvement.
Key Financial Metrics (H1 2026)
| Metric | H1 2026 ($m) | H1 2025 ($m) | Reported Growth (%) | Underlying Growth (%) |
|---|---|---|---|---|
| Revenue | 3,097 | 2,961 | 4.6 | 2.3 |
| Operating Profit | 448 | 429 | 4.3 | - |
| Trading Profit | 566 | 523 | 8.1 | - |
| Trading Profit Margin | 18.3% | 17.7% | +60 bps | - |
| EPS (Basic) | 35.6 cents | 33.5 cents | 6.2 | - |
| EPSA (Adjusted) | 47.7 cents | 42.9 cents | 11.0 | - |
| Cash from Operations | 605 | 568 | 6.9 | - |
| Free Cash Flow | 231 | 244 | (5.2) | - |
| Net Debt | 3,019 | 2,759 (Dec 2025) | - | - |
| Adjusted Leverage Ratio | 1.8x | 1.7x (Dec 2025) | - | - |
Material Changes vs. Prior Period
- Revenue Growth: H1 revenue grew 4.6% reported (2.3% underlying), impacted by one fewer trading day in 2026. Underlying growth on an Average Daily Sales (ADS) basis was 3.1%. Currency provided a 230bps tailwind.
- Profitability: Trading profit increased 8.1% to $566 million, driven by a step-up in efficiency savings ($130 million realized in H1) and tariff refunds that offset forecast headwinds. Trading profit margin expanded 60bps to 18.3%.
- Segment Performance:
- Sports Medicine & ENT: Strong growth (10.2% reported), led by Joint Repair and Arthroscopic Enabling Technologies.
- Advanced Wound Management: Flat underlying growth (-0.1%) due to headwinds in Bioactives (skin substitutes reimbursement changes) offset by growth in Wound Care and Devices.
- Orthopaedics: Flat underlying growth (-0.1%) due to challenges in US Knee and Hip implants, partially offset by growth in Trauma & Extremities.
- Cash Flow: Free cash flow decreased 5.2% to $231 million, primarily due to a $51 million increase in capital expenditure related to the new UK Wound factory and IT upgrades.
Guidance, Outlook, and Management Commentary
- Revenue Guidance Revision: Full-year revenue growth guidance has been reduced from "around 6%" to "around 4%" (underlying). Management expects H2 revenue growth to accelerate to 5.0%–5.5% (underlying), driven by new product launches and an extra trading day in Q4.
- Profit and Cash Flow Guidance: Guidance for trading profit (~8% growth excluding acquisitions), free cash flow (~$800 million), and adjusted ROIC (>10%) remains unchanged.
- Efficiency Savings: The company identified an additional $50 million in efficiency savings for 2026, bringing total expected savings to ~$200 million. This is expected to offset the impact of lower revenue growth on trading profit.
- Tariffs and Reimbursement: The net impact of tariffs is now expected to be broadly neutral due to refunds. The headwind from skin substitutes is expected to be at the upper end of the previously guided $20–$40 million range.
- Capital Allocation: A $500 million share buyback was announced in May; $216 million was settled as of August 3, 2026. The interim dividend was increased 4.0% to 15.6 cents per share.
Key Facts for Investor Verification
- US Orthopaedics Trajectory: Verify the recovery timeline for US Knee and Hip implants, specifically the impact of the LEGION MS and LANDMARK cementless launches in H2.
- Skin Substitute Stabilization: Monitor the stabilization of US skin substitute volumes and pricing following the 2026 reimbursement rule changes.
- Efficiency Execution: Confirm the realization of the additional $50 million in efficiency savings to ensure trading profit guidance is met despite lower revenue.
- Capital Expenditure: Track the completion of the UK Wound factory construction and the expected normalization of capex in H2.
- Acquisition Integration: Assess the integration progress and margin impact of the Integrity Orthopaedics acquisition ($390 million consideration).